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Abstract
Serum Antimüllerian hormone (AMH) has been shown to predict various in vitro fertilization (IVF) outcomes. AMH
and progesterone (P) are products of granulosa cells of the ovary. Since overall granulosa cell number directly
correlates with oocyte number and AMH production, the aim of this study is to evaluate whether or not serum
AMH is associated with elevated P during controlled ovarian hyperstimulation (COH) for IVF. For this retrospective
study, data were abstracted from charts of first IVF cycles of women (n = 201) who had undergone COH between
May 2014 and May 2017. Groups were as follows: (A) AMH < 1 ng/mL (n = 32), (B) AMH 1–3.99 ng/mL (n = 109), (C),
AMH ≥ 4 ng/mL (n = 60). The primary outcome measure was serum P level at trigger prior to oocyte retrieval. Mean
serum P levels among groups A, B, and C were 0.92 ng/mL, 0.96 ng/mL, and 0.84 ng/mL, respectively. One-way
ANOVA showed that there was no difference in mean serum P level among groups A, B, and C (p-value = 0.28).
Multivariable linear regression with P as the dependent variable showed that total gonadotropin dose and peak
estradiol level on day of trigger each had a significant positive relationship with P, and clinical pregnancy had a
significant negative relationship. Although AMH is a predictor of certain IVF outcomes, AMH is not a predictor of
elevated serum P level at trigger among women who undergo COH for IVF.
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Introduction
During the process of controlled ovarian hyperstimulation
(COH) for in vitro fertilization (IVF) treatment, an ele-
vated serum progesterone (P) level prior to oocyte re-
trieval may result from the multi-follicular development
which is an inherent step prior to oocyte retrieval for IVF.
This phenomenon may occur in up to 38% of COH cycles,
despite the use of gonadotropin releasing hormone
(GnRH) analogues [1–3]. Such an early rise in P level is
associated with an advancement of the endometrial micro-
architecture and the potential for embryonic-endometrial
asynchrony [4, 5]. Although controversy exists as to
whether or not an elevated serum P level on the day of ex-
ogenous follicle triggering has an effect on IVF outcomes
[6], many studies, as well as systematic reviews and
meta-analyses, have suggested that elevated P (≥ 1.5 ng/nl)
is associated with lower pregnancy rates [7, 8] among
women who undergo COH for IVF, and that a freeze-only
of embryos is recommended in that cycle, in order to
optimize outcomes by synchronizing the embryo and
endometrium in a subsequent, more natural cycle [4].
Antimüllerian Hormone (AMH) is a member of the
transforming growth factor (TGF)-β superfamily of gly-
coproteins and a widely-used serum biomarker to assess
ovarian reserve in women undergoing COH for IVF.
AMH is produced by ovarian granulosa cells which
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surround the primordial to pre-antral ovarian follicles in
which oocytes are located [9]. AMH has been shown to
be predictive of oocyte yield at retrieval as well as other
IVF outcomes [10–13], and this biomarker has been
used to optimize COH protocols that employ exogenous
gonadotropins for IVF treatment cycles [14].
Since both the steroid hormone P and the glycoprotein
AMH are products of granulosa cells [15] and since
AMH has been found to be a predictor of several IVF
outcomes, the aim of this study is to determine whether
AMH predicts the premature P rise prior to oocyte re-
trieval. If an association exists, a potential mechanism of
action may be elucidated to explain elevated P and, in
cases of intended fresh embryo transfer, patients may be
counseled about the likelihood a freeze-only of embryos
due to elevated P levels, prior to starting COH for IVF.
Methods
A retrospective chart review was performed, with data ab-
stracted from first IVF cycles of women (n = 201) who had
undergone COH at Austin Fertility & Reproductive Medi-
cine/Westlake IVF between May 2014 and May 2017. In-
clusion criteria were females between the ages of 18 and
44 years, all causes of infertility, and cases of COH with
exogenous gonadotropins. The exclusion criteria were ini-
tial intent of IVF for freeze-only either due to preimplan-
tation genetic testing (PGT) or from an elective
standpoint, COH with oral ovulation induction agents or
a combination of oral ovulation induction agents with ex-
ogenous gonadotropins, as well as donor oocyte/IVF and
donor embryo cases. Due to the de-identified nature of
the data collected, Institutional Review Board exemption
was obtained from St. David’s Healthcare Institutional Re-
view Board.
An AMH level > 1.0 ng/mL, regardless of day of the
cycle, was considered as a normal level. Group (A) con-
sisted of women with AMH< 1 ng/mL (n = 32), Group (B)
was that of women with AMH of 1–3.99 ng/mL (n = 109),
and Group (C) was comprised of women with AMH ≥ 4
ng/mL (n = 60). A high AMH threshold of 4mg/mL was
used in this study because, in our patient population, a pa-
tient is more likely to have a significantly greater ovarian
response. In addition, the authors of the following article
indicate that an increased risk of severe ovarian hyper-
stimulation syndrome, consistent with excessive ovarian
response, is generally seen in women with AMH level of
4–5 ng/mL [16]. The AMH level was measured (Ansh la-
boratories, Webster, TX) for each patient within proximity
to (at most within 6months) COH for IVF. Individualized
stimulation protocols with gonadotropin dosage and go-
nadotropin releasing hormone (GnRH) analogues based
on patient AMH level and age were used, including the
GnRH antagonist protocol which all subjects in Groups B
and C used as well as the majority of subjects in Group A
used as two subjects in that groups used the
GnRH-agonist microdose flare protocol. During ovarian
stimulation with exogenous gonadotropins, serial transva-
ginal sonograms as well as serum estradiol levels were
monitored, with P levels (Roche COBAS® Electrochemilu-
minescent immunoassay run by Clinical Pathology
Laboratories, Austin, TX) being monitored as well, after
lead follicle(s) measured 16mm or greater in average
diameter. After ovarian stimulation and subsequent trans-
vaginal ultrasound-guided oocyte retrieval 35–36 h after
human Chorionic Gonadotropin (hCG) administration, ei-
ther IVF or intracytoplasmic sperm injection (ICSI) was
performed. Embryo transfer was performed on day 3 or
day 5 based on embryo quality and in accordance with the
American Society for Reproductive Medicine (ASRM)
/Society for Assisted Reproductive Technology (SART)
guidelines for the number of embryos to be [17]. Surplus
good quality blastocysts were cryopreserved on day 5 or
day 6.
The primary outcome measure was serum P level on
the day of trigger prior to oocyte retrieval. Secondary out-
come measures were number of days of COH, total go-
nadotropin dosage during COH, number of follicles > 14
mm in average diameter on the day of trigger, estradiol
level on the day of trigger, number of M2 oocytes at re-
trieval, and number of 2 pronuclear (2PN) zygotes. Data
were expressed as means ± SD. Statistical analyses were
performed with one-way ANOVA and multivariable linear
regression. P-value < 0.05 was considered as statistically
significant.
Results
The incidence of elevated progesterone level on the day of
trigger for Groups A, B, and C were 15.6% (5/32), 12.8%
(14/109) and 1.7% (1/60), respectively (Chi square: Groups
A vs B, p = 091; Group A vs C, p = 0.03; Groups B vs C, p =
0.03). Characteristics and IVF outcomes of women in
Group A, B, and C are shown in Table 1. In terms of the
primary outcome measure, mean serum P levels among
groups A, B, and C were 0.92 ng/mL, 0.96 ng/mL, and 0.84
ng/mL, respectively; there was no statistical difference in
mean serum P level among groups A, B, and C (p-value =
0.28). In terms of secondary outcome measures, although
there were no differences among groups in for number of
days of COH (p-value = 0.73), there were statistically signifi-
cant differences among groups for total gonadotropin dos-
age during COH (p-value < 0.01), number of follicles > 14
mm in average diameter on the day of trigger (p-value <
0.01), estradiol level on the day of trigger (p-value < 0.01),
number of M2 oocytes at retrieval (p-value < 0.01), and
number of 2PN zygotes (p-value < 0.01).
A multivariable linear regression model, with P as the
dependent variable and independent variables shown in
Table 2, was fitted, with 166 cases analyzed due to
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Table 1 Variables including demographics and outcomes for study group Group A (women with AMH <1 ng/mL), study Group B
(women with AMH 1–3.99 ng/mL), and study Group C (women with AMH ≥ 4 ng/mL)
Characteristic Group A (n = 32)
AMH < 1 ng/mL
Group B (n = 109)
AMH 1–3.99 ng/mL
Group C (n = 60)
AMH ≥ 4 ng/mL
P-value
Age (years) 36.9 +/− 3.81 34.2 +/− 4.00 31.3 +/− 3.85 < 0.01
AMH (ng/mL) 0.576 +/− 0.28 2.258 +/− 0.89 6.44 +/− 2.44 < 0.01
Basal E2 (pg/mL) 21.47 +/− 12.07 19.50 +/− 8.59 23.72 +/− 11.01 0.03
Basal AFC 11.32 +/− 3.64 17.43 +/− 6.37 25.70 +/− 7.46 < 0.01
No. of days of COH 9.59 +/− 1.48 9.62 +/− 1.48 9.433 +/− 1.56 0.73
Total Gn dose (IU) 3464.06 +/− 845.41 2611.24 +/− 633.16 1838.33 +/− 636.15 < 0.01
# follicles ≥ 14 mma 5.06 +/− 2.28 9.96 +/− 4.26 15.233 +/− 6.29 < 0.01
E2 (pg/mL) at trigger 1090.20 +/− 485.52 1876.66 +/− 696.30 2371.84 +/− 890.07 < 0.01
P4 (ng/mL) at trigger 0.92 +/− 0.60 0.96 +/− 0.46 0.84 +/− 0.39 0.28
# M2 oocytes retrievedb 4.33 +/− 3.47 9.06 +/− 4.51 12.83 +/− 5.81 < 0.01
# of 2PN zygotesc 3.59 +/− 2.45 6.43 +/− 3.96 8.90 +/− 5.26 < 0.01
CPR (per fresh ET) 33.3% (8/24) 52.2% (48/92) 74.5% (38/51) < 0.01
Data are expressed as means +/− SD, and were analyzed via ANOVA*, with AMH as the independent variable for dependent variables/outcomes with the
exception of CPR which is expressed as percentages and was analyzed via Fisher’s Exact test. P-value < 0.05 was considered statistically significant
AMH = Antimüllerian hormone
AFC = antral follicle count
COH = controlled ovarian hyperstimulation
CPR = clinical pregnancy rate
E2 = estradiol
ET = embryo transfer
Gn = gonadotropin
M2 =metaphase II
P4 = progesterone
PN = pronuclear
aGroup A (n = 31)
bGroup A (n = 30), Group B (n = 108); Group C (n = 58)
cGroup A (n = 27), Group B (n = 107); Group C (n = 58)
Table 2 Multivariate linear regression model using progesterone (P4) as the dependent variable for the listed independent variables
Independent variable Progesterone (P4)
Coefficient (standard errors) P value 95% C.I.
Age (years) −0.00720 (0.00718) 0.316 (−0.214, 0.007)
AMH (ng/mL) −0.01418 (0.02127) 0.506 (−0.056, 0.028)
Basal E2 (pg/mL) 0.00106 (0.00276) 0.701 (−0.044, 0.007)
Basal AFC −0.00353 (0.00433) 0.416 (−0.012, 0.005)
No. of days of COH −0.02756 (0.02461) 0.262 (−0.076, 0.208)
Total Gn dose (IU) 0.00017 (0.00006) 0.004 * (0.000, 0.003)
# follicles ≥ 14 mma −0.00301 (0.00888) 0.735 (−0.205, 0.015)
E2 (pg/mL) at trigger 0.00001 (0.00005) 0.044 * (0.000, 0.000)
# M2 oocytes retrievedb 0.01693 (0.01208) 0.163 (−0.007, 0.041)
# of 2PN zygotesc 0.00689 (0.01218) 0.573 (−0.172, 0.031)
CPR (per fresh ET) −0.10756 (0.05308) 0.044 * (−0.212, − 0.003)
AMH = Antimüllerian hormone
AFC = antral follicle count
COH = controlled ovarian hyperstimulation
CPR = clinical pregnancy rate
E2 = estradiol
ET = embryo transfer
Gn = gonadotropin
M2 =metaphase II
P4 = progesterone
PN = pronuclear
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missing data on the covariates. Using a p < 0.05 signifi-
cance level, total gonadotropin dose and peak estradiol
level at trigger had significant positive relationships with
P, and clinical pregnancy had a significant negative rela-
tionship with P, adjusting for all of the other covariates
(Table 2). Based on the fitted model, group B had a sig-
nificantly higher mean than group A (p = 0.024) when
adjusting for the other covariates, but overall, group is
only marginally significant as a factor (p = 0.07, based on
a Wald test for the two group parameters).
Discussion
AMH has been shown to be a strong predictor of ovar-
ian response to exogenous gonadotropins during COH
for IVF as well as outcomes such as oocyte yield [18],
blastocyst formation [19], blastocyst aneuploidy [20],
and surplus embryo cryopreservation at the various
stages [21–26]. There are conflicting data regarding the
ability of AMH to predict clinical pregnancy rates and
live birth rates [27–31].
Freeze-all cycles are more common in recent years
and have been instrumental in improving overall IVF
and obstetric outcomes; however, there are data that
support fresh embryo transfer in subsets of patients [32,
33]. In such cases of patients who initially opt for fresh
embryo transfer, the inquiry as to the likelihood of
freeze-all due to an elevated progesterone level is some-
times made. A previous publication had found that
serum P level on day of trigger was associated with
serum estradiol on the day of trigger, the number of fol-
licles > 14mm, and the number of oocytes retrieved.
The authors found that basal levels of neither follicle
stimulating hormone nor estradiol were associated with
elevated P; however, AMH was not studied as a potential
predictor [34]. Since the glycoprotein AMH is produced
by granulosa cells of the ovary and since the steroid hor-
mone P is also a product of granulosa cells, we hypothe-
sized that AMH may predict elevated P levels during the
late follicular phase of COH with pituitary suppression
of LH.
In our study, a one-way ANOVA showed no difference
in mean serum P levels among women grouped into
those with AMH < 1 ng/mL, AMH 1–3.99 ng/mL and
AMH ≥ 4 ng/mL. Subsequent multivariable linear re-
gression showed that total gonadotropin dose and peak
estradiol level at trigger each had a positive relationship
with P level, and clinical pregnancy had a negative rela-
tionship with P level. There was weak evidence of group
differences based on this model when adjusting for the
other covariates, and these differences may become
more apparent in future studies with larger sample sizes.
Limitations of our study include the retrospective na-
ture with the inherent biases with such study design.
Another study limitation was the sample size,
particularly in the low AMH group (Group A). Basal
AMH levels were not checked amongst the patients,
which may be considered a minor limitation of this
study and may be a potential area to explore in future
studies. Although there may have been concerns about
luteal deficiency in PCOS, this has predominantly been
in the scenario of ovulation induction instead of the
COH protocols used for IVF. A previous study, which
involved IVF patients, showed a higher mean progester-
one level on the day of trigger among women with
PCOS when compared to women without PCOS [35].
Strengths of our study include the use of GnRH antag-
onist protocols for the vast majority of cases (94% of
subjects in Group A, 100% of subjects in Group B, and
100% subjects in Group C) as well as the use of one la-
boratory for measurement of P level. In addition, ana-
lysis of this study’s data set seemed consistent with the
existing literature in terms of showing that AMH was
associated with established factors such as ovarian re-
sponse to exogenous gonadotropins and oocyte yield at
retrieval, with there being no difference amongst groups
in terms of progesterone level on the day of trigger.
Conclusion
We conclude that although AMH is a predictor of cer-
tain IVF outcomes, AMH is not a predictor of elevated
serum P level at trigger among women who undergo
COH for IVF. Although larger studies are necessary due
to the limitations of the retrospective study design and
sample size of subjects, these data suggest that the
mechanism of action of elevated P in COH cycles is un-
likely to be due to directly proportionate granulosa cell
numbers, and from a clinical standpoint, AMH cannot
be used to counsel patients of the likelihood of a
freeze-all cycle due to elevated P if their initial intent is
fresh embryo transfer.
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